History

From lift to lab, RadioRx is the result of a chance encounter on a skiing trip between Dr. Mark Bednarski, a radiologist and professor of organic chemistry at the University of Berkeley, and a scientist working for a major defense contractor with expertise in the field of energetic materials.

From their discussion on the chair lift about the chemistry of nitrogen-rich materials and their potential medicinal applications, RadioRx was born.

Dr. Bednarski, who died of colon cancer in 2006, brought his unique and pioneering insight about the use of nitrogen-rich materials for the treatment of cancer to the lab of Dr. Susan Knox, a Stanford radiation oncologist and co-founder of RadioRx, where the new compounds were tested for activity.

An unprecedented collaboration between a venture capital firm, academia and a defense contractor, under the auspices of RadioRx, ensued to develop the highly active nitrogen-rich materials for the treatment of cancer and sickle cell disease. With a lead molecule, RRx-001, in the clinic, and follow on molecules from RadioRx’s internal research and development engine close behind, the Company is focused on their clinical development and commercialization to advance patient care in multiple unmet indications.